Achaogen Inc (AKAO) Receives $16.76 Consensus Target Price from Brokerages

Shares of Achaogen Inc (NASDAQ:AKAO) have been given a consensus rating of “Hold” by the fourteen ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $16.76.

A number of analysts have weighed in on AKAO shares. BidaskClub raised shares of Achaogen from a “hold” rating to a “buy” rating in a research report on Monday, June 18th. Cowen reissued a “buy” rating on shares of Achaogen in a research report on Friday, July 27th. Stifel Nicolaus increased their target price on shares of Achaogen from $14.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, August 7th. SunTrust Banks decreased their target price on shares of Achaogen from $16.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, August 20th. Finally, Zacks Investment Research raised shares of Achaogen from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 9th.

NASDAQ:AKAO traded up $0.16 on Wednesday, reaching $4.36. 25,631 shares of the stock traded hands, compared to its average volume of 851,615. The company has a market capitalization of $189.88 million, a PE ratio of -1.33 and a beta of 0.69. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.79 and a current ratio of 3.79. Achaogen has a 1-year low of $4.06 and a 1-year high of $16.49.

Achaogen (NASDAQ:AKAO) last released its earnings results on Monday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.19). The firm had revenue of $2.56 million for the quarter, compared to analyst estimates of $1.49 million. Achaogen had a negative net margin of 2,286.21% and a negative return on equity of 146.50%. research analysts predict that Achaogen will post -3.78 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Granahan Investment Management Inc. MA acquired a new stake in shares of Achaogen during the 2nd quarter worth approximately $1,220,000. Bank of America Corp DE grew its position in shares of Achaogen by 274.7% during the 2nd quarter. Bank of America Corp DE now owns 198,204 shares of the biopharmaceutical company’s stock worth $1,717,000 after buying an additional 145,305 shares during the period. Teton Advisors Inc. grew its position in shares of Achaogen by 324.2% during the 2nd quarter. Teton Advisors Inc. now owns 140,000 shares of the biopharmaceutical company’s stock worth $1,212,000 after buying an additional 107,000 shares during the period. Gamco Investors INC. ET AL grew its position in shares of Achaogen by 43.1% during the 2nd quarter. Gamco Investors INC. ET AL now owns 94,700 shares of the biopharmaceutical company’s stock worth $820,000 after buying an additional 28,500 shares during the period. Finally, Gabelli Funds LLC grew its position in shares of Achaogen by 18.6% during the 2nd quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock worth $1,787,000 after buying an additional 32,400 shares during the period. 60.61% of the stock is owned by institutional investors.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Featured Article: Understanding Stock Ratings

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply